Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89%

Roivant Sciences has reached a significant milestone by hitting a new 52-week high of USD 29.20 on February 25, 2026. This achievement marks a remarkable performance over the past year, with the stock surging 170.89%, significantly outpacing the S&P 500's growth of 12.95%. As a mid-cap player in the Pharmaceuticals and Biotechnology industry, Roivant Sciences boasts a market capitalization of USD 19,431 million. Despite its impressive stock performance, the company remains in a loss-making position, reflected in its price-to-earnings ratio, which is not applicable. The stock currently has a price-to-book ratio of 4.55, indicating how the market values the company relative to its book value. Additionally, Roivant Sciences has a debt-to-equity ratio of -1.06 and a return on equity of -26.15%, highlighting its financial structure and profitability challenges. The company does not offer a dividend yield, which is consistent with its focus on growth and reinvestment in its operations. This recent high underscores the dynamic nature of the stock and its position within the market.